Novo Nordisk Lifts Outlook as Wegovy Pill Drives Stronger Sales Growth
The Big Market Report Take
Novo Nordisk A/S said this year’s declines won’t be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg’s Sanne Wass reports from Copenhagen.
Go deeper: Get Morningstar's independent analyst rating, fair value estimate, and portfolio tools for this story.
Morningstar Research →Affiliate link — we may earn a commission at no cost to you.
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- Trump Pauses Hormuz Ship Plan, Seeks Iran Deal Amid War ConcernsBloomberg Markets1h ago
- ServiceNow Analyst Day Reveals Growth Strategy: What Investors Need to KnowSeeking Alpha1h ago
- Next Lifts Outlook: Robust Sales Conquer Tripled Middle East CostsBloomberg Markets1h ago